people

Asana CEO Plans to Purchase 30M Shares After Strong Q4 Earnings

[vc_row][vc_column][vc_column_text]Asana, a work management platform, saw its stock surge by 24% following the announcement that CEO Dustin Moskovitz is planning to purchase 30 million shares of the company. The plan is set to begin on March 9, 2023, and will be executed through a 10b5-1 trading plan. Moskovitz stated that he believes Asana\’s shares are […]

Asana CEO Plans to Purchase 30M Shares After Strong Q4 Earnings Read More »

UpHealth to Sell Innovations Group for $56M, Focusing on Core Offerings and Debt Reduction

[vc_row][vc_column][vc_column_text]UpHealth (NYSE:UPH) announced recently that it has reached a deal to sell Innovations Group to Belmar Pharma Solutions for approximately $56 million. The news has sent UpHealth\’s stock soaring by 11% premarket on Monday. The acquisition covers Innovations Group\’s compounding pharmacy subsidiary, MedQuest Pharmacy, and marks a significant milestone in UpHealth\’s strategy to integrate its

UpHealth to Sell Innovations Group for $56M, Focusing on Core Offerings and Debt Reduction Read More »

YPF reports strong Q4 and record annual net profit driven by higher production and prices

[vc_row][vc_column][vc_column_text]Argentina\’s state-owned oil and gas company, YPF (NYSE:YPF), reported a 69% year-on-year jump in Q4 net profit to $464 million, driven by higher production and prices. Revenues rose by 24% to $4.65 billion during the quarter. The company\’s Q4 crude oil production increased 3% quarter-on-quarter to 232,000 barrels per day, while natural gas output fell

YPF reports strong Q4 and record annual net profit driven by higher production and prices Read More »

Pliant Therapeutics Reports Q4 2022 Financial Results, Misses on EPS but Beats on Revenue

[vc_row][vc_column][vc_column_text]Pliant Therapeutics (NASDAQ: PLRX) reported its fourth quarter results on Thursday, with a GAAP loss per share of $0.72, missing analysts\’ expectations by $0.02. However, the company\’s revenue of $1.97 million, down 1.5% year-over-year, beat expectations by $0.8 million. Pliant Therapeutics is a clinical-stage biopharmaceutical company that focuses on discovering, developing, and commercializing novel treatments

Pliant Therapeutics Reports Q4 2022 Financial Results, Misses on EPS but Beats on Revenue Read More »

Ready Capital and Broadmark Realty Capital Announce Merger to Create $2.8 Billion Commercial Mortgage REIT

[vc_row][vc_column][vc_column_text]Ready Capital and Broadmark Realty Capital have announced a definitive merger deal that will create the fourth-largest commercial mortgage REIT with a capital base of $2.8 billion. Both Ready Capital (NYSE:RC) and Broadmark Realty Capital (NYSE:BRMK) are real estate finance companies that provide loans to businesses and investors. Ready Capital focuses on small and middle-market

Ready Capital and Broadmark Realty Capital Announce Merger to Create $2.8 Billion Commercial Mortgage REIT Read More »

Scroll to Top